Table 2.
Comorbidities and concomitant medications by group.
| Characteristic | HB-adMSCs 100MM, N = 33 | Placebo, N = 15 | Overall, N = 48 |
|---|---|---|---|
| Comorbidities | |||
| Number of comorbidities per subject, M (SD) | 3.5 (2.1) | 2 (1.3) | 3 (2.0) |
| Number of subjects with comorbidities, n (%) | 33 (100%) | 15 (100%) | 48 (100%) |
| Hypertension | 11 (33.3%) | 6 (40%) | 17 (35.4%) |
| Diabetes mellitus type II | 5 (15.2%) | 3 (20%) | 8 (16.7%) |
| Diabetes mellitus | 3 (9.1%) | 3 (20%) | 6 (12.5%) |
| None | 3 (9.1%) | 3 (20%) | 6 (12.5%) |
| Hyperlipidemia | 5 (15.2%) | 0 (0%) | 5 (10.4%) |
| Obesity | 4 (12.1%) | 1 (6.7%) | 5 (10.4%) |
| (For complete list, see Supplementary material) | |||
| Concomitant medications, n (%) | |||
| Number of medications per subject, M (SD) | 24.7 (15.9) | 17.2 (13.7) | 22.4 (15.5) |
| Number of subjects with concomitant medication | 32 (97%) | 14 (93.3%) | 46 (95.8%) |
| Zinc Sulfate | 29 (87.9%) | 11 (73.3%) | 40 (83.3%) |
| Atorvastatin | 26 (78.8%) | 10 (66.7%) | 36 (75%) |
| Famotidine | 24 (72.7%) | 10 (66.7%) | 34 (70.8%) |
| Melatonin | 25 (75.8%) | 9 (60%) | 34 (70.8%) |
| Methylprednisolone | 25 (75.8%) | 8 (53.3%) | 33 (68.8%) |
| Hydroxychloroquine | 23 (69.7%) | 9 (60%) | 32 (66.7%) |
| Ivermectin | 21 (63.6%) | 7 (46.7%) | 28 (58.3%) |
| Enoxaparin | 19 (57.6%) | 8 (53.3%) | 27 (56.3%) |
| Ascorbic Acid 3,000 mg/NS | 17 (51.5%) | 9 (60%) | 26 (54.2%) |
| Cholecalciferol | 19 (57.6%) | 7 (46.7%) | 26 (54.2%) |
| Parenteral Electrolytes | 17 (51.5%) | 9 (60%) | 26 (54.2%) |
| Thiamine 200 mg/D5W | 15 (45.5%) | 6 (40%) | 21 (43.8%) |
| Magnesium Sulfate 2 gm/NS | 14 (42.4%) | 6 (40%) | 20 (41.7%) |
| (For complete list, see Supplementary material) | |||
HB-adMSCs 100MM, allogeneic Hope Biosciences adipose-derived MSCs 1×108 cells. Comorbidities with 5 or more occurrences and medications with 20 or more occurrences in the overall sample are listed in the table. For full list of medications and comorbidities by group, see Supplementary Table S1.